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b Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, USAThe editors of Contemporary Issues in Women's Health solicit
reporters and correspondents from throughout the world to make
contributions to this section. Please feel free to email Doctor Richard
Adanu at rmadanu@yahoo.com or Doctor Maya Hammoud at
immaya@umich.edu if you have reports or items that you would like
included.Wewould be happy to attribute the items to those reporters
and correspondents who give permission in their transmittal.
Otherwise, we will share those reports that we think are of the
greatest interest to our readership without attribution.
New guidelines for breast cancer screening cause controversy
TheUS Preventive Services Task Force (USPSTF) has released revised
recommendationsonbreast cancer screeningamidmuchcontroversy in
the United States. The new guidelines, published in the November 2009
issue of Annals of Internal Medicine [1], recommend against screening
mammography for women in their 40s and recommend screening only
once every two years for women aged between 50 and 74. This differs
from the American Cancer Society (ACS) guidelines that recommend
screening yearly beginning at 40 years and the American College of
Obstetricians and Gynecologists (ACOG) who recommend screening
mammography for women every 1–2 years between the ages of 40 and
50 years and yearly thereafter [2]. Furthermore, the USPSTF recom-
mends against teaching women how to perform a breast self-exam
(BSE). ACOG's position remains to counsel women that BSE has the
potential to detect palpable breast cancer.
The new USPSTF recommendations are based on a systematic
evidence review by Dr Heidi D. Nelson [3] and a modeling estimates
study on potential benefits and harms of different screening schedules
by Dr Jeanne S. Mandelblatt [4]. Based on these analyses, the 2009
USPSTF concluded that women should not be getting mammograms
in their 40s because they experience greater harms from screening
than women in their 50s including additional imaging, biopsies, and
psychological stress. Furthermore, although the benefit of screening
women in their 40s is the same as women in their 50s, 1904 women
between the ages of 39 and 49 need to be screened to prevent one
cancer death comparedwith 1339 women between the ages of 50 and⁎ Corresponding authors.
E-mail addresses: rmadanu@yahoo.com (R.M.K. Adanu), immaya@umich.edu
(M.M. Hammoud).
1 Senior Lecturer, Department of Obstetrics and Gynecology, University of Ghana
Medical School, PO Box 4236, Accra, Ghana.
2 Adjunct Assistant Professor, Department of Obstetrics and Gynecology, University
of Michigan Medical School, Ann Arbor, MI, 48109, USA.
doi:10.1016/j.ijgo.2009.12.00859. The Mandelblatt modeling study states: “If the goal of a national
screening program is to reducemortality in themost efficientmanner,
then programs that screen biennially from age 50 years to age 69, 74,
or 79 years are among the most efficient on the basis of the ratio
of benefits to the number of screening examinations. If the goal of a
screening program is to efficiently maximize the number of life-years
gained, then the preferred strategy would be to screen biennially
starting at age 40 years. Decisions about the best starting and stopping
ages also depend on tolerance for false-positive results and rates of
overdiagnosis” [4].
The major concerns stem from the fact that those recommenda-
tions may be adopted as policy and Medicare and private insurers will
no longer pay for these services to cut costs. Many have suggested that
the USPSTF, a federally supported body, is indeed trying to cut costs as
these recommendations come at the same time the US government is
trying to cut costs. Interestingly, these new recommendations are
similar to those adopted in other high-income countries. For example,
in England, screening mammograms are offered to women aged
between 47 and 70 every 3 years; in France, they are offered every
2 years from age 50 to 74; in Canada, mammograms are recom-
mended every 2 years between the age of 50 and 69. Regardless of
what the “best” screening schedule should be, these new recommen-
dations have caused much confusion among the lay public; however,
it is most important to remember that recommendations are intended
as guidance. The decision whether to screen or not should be left up to
the woman and a discussion with her physician.
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Vaginal hysterectomy is the approach of choice when feasible
Hysterectomy is one of the most common surgical procedures
performed for women in the United States, at a rate of 4.81 per 1000
woman-years. This is similar or higher than rates reported in other
4 R.M.K. Adanu, M.M. Hammoud / International Journal of Gynecology and Obstetrics 109 (2010) 3–4industrialized countries (e.g., 4.80 in Australia and 3.46 in Canada).
With advances in technology and the ability to perform hysterecto-
mies laparoscopically with or without robotic assistance, it is im-
portant to continually assess the safest approach to the procedure. The
American College of Obstetricians and Gynecologists (ACOG) released
an ACOG Committee Opinion (Number 444) in November 2009 [1]
concluding that vaginal hysterectomy (VH) is associated with better
outcomes and fewer complications than laparoscopic (LH) or abdom-
inal hysterectomy (AH).
Vaginal hysterectomy, whenever feasible, has been cited as the
safest and most cost-effective approach in most of the literature,
including a Cochrane Review updated in 2009 [2]. The benefits of VH
versus AH were speedier return to normal activities, fewer febrile
episodes, and lower intraoperative blood loss. LH was also found to
have benefits over AH including all the above and fewer abdominal
infections, but the operative time was longer and there were more
urinary tract infections. There was no evidence of benefits of LH over
VH, and the operative time and substantial bleeding were higher in
LH. Experience with robotic-assisted surgeries remains limited to
draw any conclusions of benefits and risks. Despite these findings, in
the United States, AH is still performed in 66% of cases, VH in 22%, and
LH in 12% of cases. Obviously, there are many factors that influence
the approach to a hysterectomy, including the size and shape of
the uterus and vagina, the extent of extrauterine disease and prior
procedures performed on the patient, surgeon training and experi-
ence, available equipment and support, as well as preference of the
patient. However, vaginal hysterectomy is the approach of choice
whenever feasible, based on its well-documented advantages and
lower complication rates.
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A report with the above title was commissioned by Dr Margaret
Chan, Director General of the World Health Organization. The report
examines women's health needs and their contribution to the health
of societies. This report uses a life-course approach to investigate
issues that are peculiar to the health of women globally. It highlights
the consequences and costs of not addressing health issues at the
appropriate points of women's lives.
The key findings of the report are as follows:
• There are widespread and persistent inequities in health and
healthcare between women and men.
• The central issue in the area of women's health is related to sexuality
and reproduction.
• Chronic diseases, injuries, and mental issues have become major
sources of morbidity and mortality for women.• To improve the health of women it is critical for girls to have a fair
start on the road to health.
• Societies and health systems worldwide continue to fail women.
The following were identified as key areas for reform:
• Building strong leadership and a coherent institutional response to
women's health issues.
• Getting health systems to work for women.
• Leveraging changes in public policy to produce healthier societies.
• Building the knowledge base and monitoring progress in the health
of women.
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pdf.New HIV recommendations by the World Health Organization
The World Health Organization has produced new recommenda-
tions for the management of HIV infection. Implementation of these
recommendations is expected to result in reduced infections and
more lives saved. It is currently estimated that there are almost
34 million people living with HIV/AIDS, with close to 3 million new
infections each year. It is an accepted fact that HIV/AIDS is the leading
worldwide cause of mortality among women of reproductive age.
For HIV treatment, WHO currently recommends that antiretroviral
therapy (ART) be started at a CD4 threshold of 350 cells/mL for all HIV
patients regardless of symptoms. This also applies to pregnant
women. Countries are being asked to phase out the use of stavudine
(d4T) because of its adverse effects. Zidovudine (AZT) or tenofovir
(TDF) are recommended as effective alternatives.
To improve prevention of mother-to-child transmission, ART
should be initiated at 14 weeks of gestation and continued to the
end of the breastfeeding period. HIV positive women who choose to
breastfeed can do so until the infant is 12 months of age provided the
mother or baby is on ART.
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aids_20091130/en/index.html.Women's health: useful sources of information
Macro International together with National Statistical Services con-
ducts Demographic Health Surveys in many low-income countries.
These surveys focus on maternal and child health and for most of these
countries they provide the most reliable data on the population health
parameters of women and children. Free access to survey reports can be
obtained at: http://www.measuredhs.com. People interested in gaining
access to the survey data can register for free access.
The WHO Library Database can be accessed at: http://dosei.who.
int. Publications and documents from WHO, in multiple languages,
can be downloaded from this site for free. The site also provides the
means for users to search the database using search terms.
